AspenBio scraps AppyScore ELISA test after second trial disappointment
This article was originally published in Clinica
Executive Summary
AspenBio Pharma does not plan to file a second 510(k) application with the US FDA for the ELISA version of its troubled AppyScore appendicitis blood test.